Literature DB >> 23935329

Successful treatment with Rituximab in a patient with life-threatening resistant Thrombotic Thrombopenic Purpura.

Ge Theodoropoulos1, S Arampatzi, Md Diamantidis, V Perifanis, E Diza, G Kaiafa.   

Abstract

Entities:  

Keywords:  acquired thrombotic thrombocytopenic purpura; plasmapheresis; rituximab

Year:  2012        PMID： 23935329      PMCID： PMC3738624     

Source DB:  PubMed          Journal:  Hippokratia        ISSN： 1108-4189            Impact factor:   0.471


× No keyword cloud information.
  3 in total

1.  Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a single-institution experience.

Authors:  Hande H Tuncer; Robert A Oster; Shu T Huang; Marisa B Marques
Journal:  Transfusion       Date:  2007-01       Impact factor: 3.157

2.  von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

Authors:  M Furlan; R Robles; M Galbusera; G Remuzzi; P A Kyrle; B Brenner; M Krause; I Scharrer; V Aumann; U Mittler; M Solenthaler; B Lämmle
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

Review 3.  Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature.

Authors:  Mischelle A Elliott; John A Heit; Rajiv K Pruthi; Dennis A Gastineau; Jeffrey L Winters; C Christopher Hook
Journal:  Eur J Haematol       Date:  2009-06-08       Impact factor: 2.997
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.